Evidence map›Paper›PMID 34614013›Full record

ArticlePloS one2021

Alpha-mannosidosis in Tunisian consanguineous families: Potential involvement of variants in GHR and SLC19A3 genes in the variable expressivity of cognitive impairment.

Rahma Mkaouar, Zied Riahi, Cherine Charfeddine, Imen Chelly, Hela Boudabbous, Hamza Dallali, Crystel Bonnet, Meriem Hechmi, Soumeya Bekri, Nadia Zitouna and 17 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 9 institutions in 2 countries.

Rahma MkaouarLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.ORCID 0000-0002-1663-672X
Zied RiahiLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.
Cherine CharfeddineLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.
Imen ChellyDepartment of Paediatrics, Habib Bougatfa Hospital, Bizerte, Tunisia.
Hela BoudabbousDepartment of Paediatrics and Metabolic Diseases EPS La Rabta Hospital in Tunis, Tunis, Tunisia.
Hamza DallaliLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.
Crystel BonnetHearing Institute, Pasteur Institute, INSERM, Paris, France.
Meriem HechmiLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.
Soumeya BekriLaboratory of Medical Biochemistry, Institute of Clinical Biology, University Hospital in Rouen, Rouen, France.
Nadia ZitounaLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.
Lotfi ZekriLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.
Amel TounsiICHARA association (International Research Institute on Sign Language), Tunis, Tunisia.
Rym KefiLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.
Jihene MarrakchiLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.
Olfa MessaoudLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.
Ichraf KraouaDepartment of Child Neurology, LR 18SP04, National Institute Mongi Ben Hmida of Neurology in Tunis, University of Tunis El Manar, Tunis, Tunisia.
Sonia MaalejDepartment of Pneumology-Abderahman Mami Hospital in Ariana, Ariana, Tunisia.
Ilhem Turki Ben YoussefDepartment of Child Neurology, LR 18SP04, National Institute Mongi Ben Hmida of Neurology in Tunis, University of Tunis El Manar, Tunis, Tunisia.
Ahlem Ben HmidLaboratory of clinical immunology, Pasteur Institute in Tunis, Tunis, Tunisia.
Fabrice GiraudetFaculty of Medicine, Neurosensory Biophysics, INSERM 1107, University of Clermont Auvergne, Clermont-Ferrand, France.
Sami BouchouchaLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.
Neji TebibDepartment of Paediatrics and Metabolic Diseases EPS La Rabta Hospital in Tunis, Tunis, Tunisia.
Ghazi BesbesFaculty of Medicine in Tunis, Laboratory of Hereditary Diseases of the Metabolism Investigation and Patients Management, University of Tunis El Manar, Tunis, Tunisia.
Christine PetitHearing Institute, Pasteur Institute, INSERM, Paris, France.
Ridha MradDepartment of Congenital and Hereditary Diseases, Charles Nicolle Hospital in Tunis, Tunis, Tunisia.
Sonia AbdelhakLaboratory of Biomedical Genomics and Oncogenetics LR20IPT05-Pasteur Institute in Tunis, Tunis, Tunisia.
Mediha TrabelsiDepartment of Congenital and Hereditary Diseases, Charles Nicolle Hospital in Tunis, Tunis, Tunisia.
Institut Pasteur de Tunis · TNHôpital La Rabta · TNInserm · FRTunis University · TNHôpital Charles-Nicolle · TNAbderrahmane Mami Hospital · TNHopital Universitaire Habib Bourguiba · TNLaboratoire de Biochimie · FRUniversity of Carthage · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alpha-Mannosidosis (AM) is an ultra-rare storage disorder caused by a deficiency of lysosomal alpha-mannosidase encoded by the MAN2B1 gene. Clinical presentation of AM includes mental retardation, recurrent infections, hearing loss, dysmorphic features, and motor dysfunctions. AM has never been reported in Tunisia. We report here the clinical and genetic study of six patients from two Tunisian families with AM. The AM diagnosis was confirmed by an enzymatic activity assay. Genetic investigation was conducted by Sanger sequencing of the mutational hotspots for the first family and by ES analysis for the second one. In the first family, a frameshift duplication p.(Ser802GlnfsTer129) was identified in the MAN2B1 gene. For the second family, ES analysis led to the identification of a missense mutation p.(Arg229Trp) in the MAN2B1 gene in four affected family members. The p.(Ser802GlnfsTer129) mutation induces a premature termination codon which may trigger RNA degradation by the NMD system. The decrease in the levels of MAN2B1 synthesis could explain the severe phenotype observed in the index case. According to the literature, the p.(Arg229Trp) missense variant does not have an impact on MAN2B1 maturation and transportation, which correlates with a moderate clinical sub-type. To explain the intra-familial variability of cognitive impairment, exome analysis allowed the identification of two likely pathogenic variants in GHR and SLC19A3 genes potentially associated to cognitive decline. The present study raises awareness about underdiagnosis of AM in the region that deprives patients from accessing adequate care. Indeed, early diagnosis is critical in order to prevent disease progression and to propose enzyme replacement therapy.

Indexed as

ConsanguinityGenetic Predisposition to Diseasealpha-MannosidosisAudiometryBase SequenceCarrier ProteinsCognitive DysfunctionExome SequencingFamilyFemaleGeographyHumansMaleMembrane Transport ProteinsMutationPedigreeCarrier ProteinsMembrane Transport ProteinsSLC19A3 protein, humansomatotropin-binding protein

Identifiers

PMID34614013
PMCPMC8494324
OpenAlexW3204303758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.